Business And Pharmaceuticals News

The latest business and pharmaceuticals stories, summarized by AI

business-and-pharmaceuticals0.56 min read

Novo Nordisk Acquires Cardior for $1.1 Billion to Expand Cardiovascular Portfolio

Novo Nordisk is set to acquire German biotech Cardior Pharmaceuticals, a Phase 2 RNA startup, for up to $1.1 billion in a move to strengthen its presence in cardiovascular disease, following the recent label expansion of its obesity drug Wegovy to include the reduction of cardiovascular events. This acquisition marks a strategic shift for Novo, which had previously focused on obesity-related acquisitions.

1 year ago•Source: Endpoints News

Gilead's $4.3 Billion Acquisition of CymaBay Sends Stock Soaring

business-and-pharmaceuticals

0.725 min•1 year ago

Gilead's $4.3 Billion Acquisition of CymaBay Sends Stock Soaring

Gilead has announced its acquisition of CymaBay Therapeutics for $4.3 billion, just ahead of the FDA's expected decision on CymaBay's rare liver disease drug candidate, selexipag. The deal, valued at $32.50 per share, represents a 27% premium to CymaBay's closing price on Friday. CymaBay's drug has shown promise in treating primary biliary cholangitis, a rare chronic disease that primarily affects women in the US, with the FDA's approval decision deadline set for August 14.

via Endpoints News

Featured Business And Pharmaceuticals Stories

Novo Nordisk Acquires Cardior for $1.1 Billion to Expand Cardiovascular Portfolio

Gilead's $4.3 Billion Acquisition of CymaBay Sends Stock Soaring

More Business And Pharmaceuticals Stories